HC Wainwright Forecasts Lower Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Stock analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of Rockwell Medical in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.03) per share for the quarter, down from their prior estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.10) EPS.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. The business had revenue of $24.67 million during the quarter, compared to the consensus estimate of $23.65 million.

Separately, StockNews.com cut Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Rockwell Medical Price Performance

Shares of RMTI opened at $1.24 on Wednesday. Rockwell Medical has a fifty-two week low of $1.18 and a fifty-two week high of $5.15. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. The stock has a market cap of $40.08 million, a PE ratio of -24.80 and a beta of 1.55. The firm’s 50-day simple moving average is $1.80 and its two-hundred day simple moving average is $2.57.

Institutional Investors Weigh In On Rockwell Medical

Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in shares of Rockwell Medical in the 4th quarter worth $28,000. Two Sigma Securities LLC bought a new position in Rockwell Medical in the fourth quarter worth approximately $33,000. Barclays PLC increased its holdings in Rockwell Medical by 27.5% during the 4th quarter. Barclays PLC now owns 28,854 shares of the company’s stock worth $59,000 after purchasing an additional 6,229 shares during the period. XTX Topco Ltd increased its holdings in Rockwell Medical by 58.0% during the 4th quarter. XTX Topco Ltd now owns 44,962 shares of the company’s stock worth $92,000 after purchasing an additional 16,507 shares during the period. Finally, LPL Financial LLC raised its holdings in shares of Rockwell Medical by 91.3% in the fourth quarter. LPL Financial LLC now owns 54,872 shares of the company’s stock valued at $112,000 after acquiring an additional 26,191 shares in the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.